Neisseria Meningitidis Serogroup W-135 Tetanus Toxoid Conjugate Vaccine
This vaccine protects against Neisseria meningitidis serogroup W-135, a bacterial pathogen that causes meningococcal meningitis and septicemia. It is a conjugate vaccine that links capsular polysaccharides to tetanus toxoid protein, enhancing immune response and providing longer-lasting protection compared to plain polysaccharide vaccines. The vaccine is particularly recommended for travelers to regions where serogroup W-135 is endemic or epidemic, including Hajj pilgrims, and for outbreak control situations.
A conjugate vaccine providing protection against meningococcal disease caused by serogroup W-135 bacteria.
Key facts at a glance
- RxNorm
- 2360573
- Generic
- Neisseria Meningitidis Serogroup W-135 Capsular Polysaccharide Tetanus Toxoid Protein Conjugate Vaccine
- Class
- unclassified
- Brands
- Menquadfi, Penbraya
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup W-135, including meningitis and meningococcemia. Indicated for active immunization of individuals traveling to or residing in areas where W-135 is endemic or epidemic, particularly the African meningitis belt, and for Hajj pilgrims (required by Saudi Arabia). May also be used in outbreak situations involving this serogroup.
This conjugate vaccine works by stimulating the immune system to produce antibodies against the polysaccharide capsule of Neisseria meningitidis serogroup W-135. The tetanus toxoid protein carrier converts the T-cell independent polysaccharide antigen into a T-cell dependent antigen, producing a stronger and more durable immune response with enhanced immunological memory. This conjugation technology makes the vaccine effective even in young children.
Common adverse reactions include injection site pain, redness, and swelling; systemic reactions may include headache, fatigue, and mild fever. Contraindicated in individuals with known hypersensitivity to any vaccine component. Safety during pregnancy should be evaluated by a healthcare provider. Vaccination does not provide protection against other meningococcal serogroups. Booster recommendations vary by country and risk factors.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 29, 2026. · Read our editorial policy